News

8 February 2018

Immunocore Announces Leadership Change

4 January 2018

Immunocore Strengthens its Board with Appointments of Laura Wade-Gery and Kristine Peterson as Non-Executive Directors

11 December 2017

Immunocore’s IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma

13 November 2017

Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate

31 October 2017

Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

4 October 2017

Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer

18 September 2017

Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases

7 July 2017

Immunocore and MEPC announce significant laboratory expansion at Milton Park in Oxfordshire, UK

3 July 2017

Immunocore Announces Third Oncology Target Selected in Discovery Collaboration with GlaxoSmithKline

5 June 2017

Immunocore Announces Compelling Single Agent IMCgp100 Clinical Data in Metastatic Uveal Melanoma at ASCO 2017 Annual Meeting

News archive